TuHURA Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-21.68	-29.32	-9.37
Depreciation & Amortization	0.12	0.18	0.37
Other Amortization	1.28	0.01	-
Asset Writedown & Restructuring Costs	-	16.22	-
Stock-Based Compensation	1.96	0.48	0.22
Other Operating Activities	0.31	-	-0.29
Change in Accounts Payable	3.64	0.34	1.85
Change in Other Net Operating Assets	-0.36	0.15	-0.29
Operating Cash Flow	-14.73	-11.95	-7.51
Capital Expenditures	-0.06	-1.3	-0.04
Cash Acquisitions	-5.99	-	-
Investing Cash Flow	-6.05	-1.3	-0.04
Long-Term Debt Issued	28.57	2.69	-
Long-Term Debt Repaid	-0.8	-	-0.35
Net Debt Issued (Repaid)	27.77	2.69	-0.35
Issuance of Common Stock	7.05	-	-
Repurchase of Common Stock	-	-0.02	-
Other Financing Activities	-5.05	-	-
Financing Cash Flow	29.77	2.66	16.25
Net Cash Flow	8.99	-10.59	8.71
Free Cash Flow	-14.79	-13.25	-7.54
Free Cash Flow Per Share	-0.79	-1.11	-
Levered Free Cash Flow	-15.19	-8.29	-
Unlevered Free Cash Flow	-13.88	-8.29	-
Change in Net Working Capital	4.86	-0.82	-

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q